What is the recommended antibiotic escalation strategy and dosing for a patient with a skin infection, including empiric coverage, adjustments for penicillin allergy, renal impairment, and the addition of anti‑pseudomonal or anti‑MRSA agents as needed?

Antibiotic Escalation and Dosing for Skin Infections

For outpatient skin infections, start with clindamycin 300-450 mg PO three times daily or TMP-SMX 1-2 double-strength tablets twice daily for purulent cellulitis to cover CA-MRSA, or a beta-lactam (cephalexin 500 mg four times daily) for nonpurulent cellulitis targeting streptococci; escalate to IV vancomycin 15 mg/kg every 8-12 hours or linezolid 600 mg twice daily for hospitalized complicated infections, adding piperacillin-tazobactam 4.5 g every 6 hours if Pseudomonas coverage is needed.

Initial Empiric Coverage Strategy

The approach depends on whether the infection is purulent (with drainage/exudate) or nonpurulent (no drainage):

Outpatient Purulent Cellulitis

• Primary pathogens: CA-MRSA (streptococcal coverage likely unnecessary) 1
• First-line oral options:
  • Clindamycin 300-450 mg PO three times daily 1
  • TMP-SMX 1-2 double-strength tablets twice daily 1
  • Doxycycline or minocycline 100 mg twice daily 1
  • Linezolid 600 mg twice daily (more expensive) 1
• Duration: 5-10 days based on clinical response 1

Outpatient Nonpurulent Cellulitis

• Primary pathogens: Beta-hemolytic streptococci 1
• First-line: Beta-lactam such as cephalexin 500 mg four times daily or dicloxacillin 500 mg four times daily 2, 1
• Escalation trigger: Add MRSA coverage if no response to beta-lactam or systemic toxicity present 1
• Dual coverage options (streptococci + MRSA):
  • Clindamycin alone 1
  • TMP-SMX or tetracycline PLUS amoxicillin 1
  • Linezolid alone 1

Hospitalized Complicated Skin Infections

For complicated SSTI (deeper infections, major abscesses, surgical wounds, infected ulcers/burns):

Anti-MRSA Coverage (Empiric)

• Vancomycin 15 mg/kg IV every 8-12 hours (target trough 15-20 mg/mL) 1
• Linezolid 600 mg IV/PO twice daily 1
• Daptomycin 4 mg/kg IV once daily 1
• Telavancin 10 mg/kg IV once daily 1
• Clindamycin 600 mg IV/PO three times daily (if local resistance <10%) 1
• Duration: 7-14 days based on clinical response 1, 3

When to Add Gram-Negative/Pseudomonal Coverage

Add anti-pseudomonal agents if:

• Nosocomial acquisition
• Immunocompromised state
• Structural tissue damage
• Water-related injury (Aeromonas, Vibrio)

Anti-pseudomonal options:

• Piperacillin-tazobactam 4.5 g IV every 6 hours 4
• Cefepime 2 g IV every 8 hours 4
• Meropenem 1 g IV every 8 hours 4
• Ciprofloxacin 400 mg IV every 8 hours 4

Penicillin Allergy Adjustments

Non-Severe Allergy (Rash, Drug Fever)

• Safe to use: Cephalosporins (cefazolin, cephalexin, cefepime) 5
• Cross-reactivity risk is low for non-IgE reactions

Severe Allergy (Anaphylaxis, Hives)

• Avoid all beta-lactams 5
• Alternative regimens:
  • For MRSA: Vancomycin, linezolid, daptomycin, or clindamycin 1
  • For Pseudomonas: Aztreonam 2 g IV every 8 hours PLUS vancomycin (aztreonam does not cross-react) 4
  • For streptococci: Clindamycin or fluoroquinolone 1

Critical caveat: If aztreonam is used for severe penicillin allergy, you must add separate MSSA coverage since aztreonam lacks gram-positive activity 4.

Renal Impairment Dosing

General Principles

• Reduce dose by approximately 30% for each level of renal impairment (moderate/severe) 6
• Most beta-lactams and vancomycin require adjustment 6, 7
• Consider therapeutic drug monitoring, especially for vancomycin 7

Specific Adjustments for Common Agents

Vancomycin:

• Monitor trough levels closely; target 15-20 mg/mL 1
• Dose based on actual renal function and levels 7

Piperacillin-tazobactam:

• CrCl 20-40: 3.375 g every 6 hours
• CrCl <20: 2.25 g every 6 hours 7

Cefepime:

• CrCl 30-60: 2 g every 12 hours
• CrCl 11-29: 2 g every 24 hours 7

Meropenem:

• CrCl 26-50: 1 g every 12 hours
• CrCl 10-25: 500 mg every 12 hours 7

No adjustment needed:

• Linezolid (not renally cleared) 7
• Daptomycin (dose once daily; adjust for CrCl <30) 7
• Clindamycin (hepatically metabolized) 7

Hemodialysis Considerations

• Administer dose immediately after dialysis session for drugs cleared by dialysis (vancomycin, beta-lactams) 6
• Linezolid and daptomycin: minimal removal by dialysis 6

Key Clinical Pitfalls

Do not use rifampin as monotherapy or adjunctive therapy for skin infections—no benefit demonstrated 1, 3.

Tetracyclines contraindicated in children <8 years and pregnancy 1.

TMP-SMX is pregnancy category C/D; avoid in third trimester and infants <2 months 1.

Clindamycin resistance: Check local resistance rates; use only if <10% resistance for empiric therapy in serious infections 1.

Culture before antibiotics: Obtain cultures from purulent infections in patients with severe disease, systemic illness, treatment failure, or outbreak concern 1, 3.

Source control is mandatory: Incision and drainage for abscesses, surgical debridement for necrotizing infections—antibiotics alone are insufficient 1, 3, 8.

Pediatric Dosing

Vancomycin: 15 mg/kg IV every 6 hours 1

Clindamycin: 10-13 mg/kg/dose IV every 6-8 hours (max 40 mg/kg/day) 1

Linezolid:

• 12 years: 600 mg twice daily

• <12 years: 10 mg/kg every 8 hours 1

TMP-SMX: 4-6 mg/kg/dose (trimethoprim component) every 12 hours 1